RS64942B1 - Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema - Google Patents

Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema

Info

Publication number
RS64942B1
RS64942B1 RS20231190A RSP20231190A RS64942B1 RS 64942 B1 RS64942 B1 RS 64942B1 RS 20231190 A RS20231190 A RS 20231190A RS P20231190 A RSP20231190 A RS P20231190A RS 64942 B1 RS64942 B1 RS 64942B1
Authority
RS
Serbia
Prior art keywords
compositions
preparation
delivery agent
delivery
agent
Prior art date
Application number
RS20231190A
Other languages
English (en)
Inventor
Thomas Vilhelmsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49221869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS64942(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of RS64942B1 publication Critical patent/RS64942B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20231190A 2012-03-22 2013-03-15 Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema RS64942B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12160742 2012-03-22
US201361748844P 2013-01-04 2013-01-04
EP13153422 2013-01-31
EP18212576.5A EP3542790B1 (en) 2012-03-22 2013-03-15 Compositions comprising a delivery agent and preparation thereof

Publications (1)

Publication Number Publication Date
RS64942B1 true RS64942B1 (sr) 2024-01-31

Family

ID=49221869

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20190386A RS58636B1 (sr) 2012-03-22 2013-03-15 Kompozicije koje sadrže sredstvo za isporuku i njihova priprema
RS20231190A RS64942B1 (sr) 2012-03-22 2013-03-15 Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20190386A RS58636B1 (sr) 2012-03-22 2013-03-15 Kompozicije koje sadrže sredstvo za isporuku i njihova priprema

Country Status (11)

Country Link
US (1) US10335369B2 (sr)
EP (3) EP2827845B1 (sr)
JP (1) JP6356660B2 (sr)
CN (3) CN104203221A (sr)
ES (1) ES2965469T3 (sr)
HR (1) HRP20231613T1 (sr)
HU (1) HUE064694T2 (sr)
PL (2) PL2827845T3 (sr)
RS (2) RS58636B1 (sr)
SI (1) SI2827845T1 (sr)
WO (1) WO2013139695A1 (sr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5902194B2 (ja) 2010-12-16 2016-04-13 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
ES2612278T3 (es) 2011-04-12 2017-05-16 Novo Nordisk A/S Derivados de GLP-1 doble-acilados
ES2952874T3 (es) * 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
JP6356660B2 (ja) 2012-03-22 2018-07-11 ノヴォ ノルディスク アー／エス 送達剤を含む組成物およびその調製
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
MY172578A (en) 2013-05-02 2019-12-03 Novo Nordisk As Oral dosing of glp-1 compounds
CN104173313B (zh) * 2014-08-25 2017-05-17 杭州朱养心药业有限公司 利伐沙班片剂药物组合物
US9833411B2 (en) 2015-01-12 2017-12-05 Enteris Biopharma, Inc. Solid oral dosage forms
WO2018121702A1 (zh) * 2016-12-30 2018-07-05 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN113329810A (zh) * 2019-01-24 2021-08-31 诺和诺德股份有限公司 辊压机和使用辊压机的干法制粒方法
WO2021023855A1 (en) * 2019-08-07 2021-02-11 Novo Nordisk A/S Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN114340655A (zh) 2019-09-02 2022-04-12 诺和诺德股份有限公司 生产包含glp-1肽的片剂的方法
US20220323360A1 (en) 2019-09-06 2022-10-13 Novo Nordisk A/S Method and equipment for fractionation of granules for use in pharmaceutical compositions
US20220395559A1 (en) 2019-11-07 2022-12-15 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP2023524695A (ja) * 2020-04-29 2023-06-13 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
CN116157414A (zh) * 2020-07-22 2023-05-23 诺和诺德股份有限公司 Glp-1和gip受体共激动剂
BR112023000270A2 (pt) * 2020-07-22 2023-01-31 Novo Nordisk As Composto, composição farmacêutica, e, peptídeo
CN113117050B (zh) * 2021-05-06 2022-04-26 合肥天汇孵化科技有限公司 多肽组合物及其用途
AU2022269659A1 (en) 2021-05-07 2023-11-02 Eli Lilly And Company Erodible tablet
WO2023285580A1 (en) 2021-07-15 2023-01-19 Novo Nordisk A/S Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
TW202333774A (zh) * 2021-12-01 2023-09-01 大陸商江蘇恆瑞醫藥股份有限公司 Glp-1和gip受體雙重激動劑的醫藥組成物及其用途
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059366T3 (es) 1986-03-12 1994-11-16 American Cyanamid Co Compuestos macrolidos.
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
ES2301477T3 (es) 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
WO2001092206A1 (en) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
JP5196701B2 (ja) 2001-11-29 2013-05-15 エミスフィアー テクノロジーズ インコーポレイテッド クロモリンナトリウムの経口投与用製剤
JP2005526020A (ja) 2002-02-01 2005-09-02 ファイザー・プロダクツ・インク アジスロマイシンの乾式造粒配合物
BR0307727A (pt) 2002-02-20 2005-01-25 Lilly Co Eli Fomulação
JP2004131398A (ja) * 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
NZ543274A (en) 2003-05-14 2007-12-21 Emisphere Tech Inc Compositions for delivering peptide YY and PYY agonists
ES2330638T3 (es) 2003-07-11 2009-12-14 Novartis Ag Composiciones farmaceuticas dosificadas en forma oral que contienen un agente de suministro en forma micronizada.
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
RU2006120077A (ru) 2003-12-18 2008-01-27 Ново Нордиск А/С (DK) Аналоги глюкагоноподобного пептида-1 (glp-1), связанные с альбуминоподобными агентами
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
BRPI0510226A (pt) 2004-05-06 2007-10-23 Emisphere Tech Inc composição farmacêutica sólida, forma de dosagem sólida, método para administrar heparina a um animal, método para tratar ou evitar trombose em um animal, método para preparar uma forma de dosagem sólida de heparina umidecida
NZ551196A (en) 2004-05-14 2010-08-27 Emisphere Tech Inc Compounds and compositions for delivering active agents
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
CN101128214A (zh) 2005-03-18 2008-02-20 诺和诺德公司 长效glp-1化合物
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20080260818A1 (en) 2005-03-28 2008-10-23 Dexcel Pharma Technologies Ltd. Controlled Absorption of Statins in the Intestine
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US20080255048A1 (en) 2005-11-17 2008-10-16 Moise Azria Pharmaceutical Composition
EP2007397B1 (en) 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
CA2656019C (en) * 2006-06-28 2016-09-13 Emisphere Technologies, Inc. Gallium nitrate formulations
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
ES2498519T3 (es) 2006-09-07 2014-09-24 F. Hoffmann-La Roche Ag Un procedimiento para la fabricación de SNAC (SALCAPROZATO SÓDICO)
AR062925A1 (es) 2006-09-22 2008-12-17 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
US20100069410A1 (en) 2006-12-01 2010-03-18 Emisphere Technologies Inc. acyclovir formulations
ES2365648T3 (es) 2007-03-02 2011-10-07 Novartis Ag Administración oral de una calcitonina.
US20110183889A1 (en) 2007-08-29 2011-07-28 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
WO2009030774A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
BRPI0818004B8 (pt) 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
US8022048B2 (en) 2007-11-02 2011-09-20 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
EP2395988A2 (en) 2009-02-13 2011-12-21 Boehringer Ingelheim International GmbH Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
WO2011084618A2 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2011116139A2 (en) 2010-03-16 2011-09-22 Chiasma Inc. Improved pharmaceutical compositions and methods of delivery
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
JP5902194B2 (ja) 2010-12-16 2016-04-13 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
JP6356660B2 (ja) 2012-03-22 2018-07-11 ノヴォ ノルディスク アー／エス 送達剤を含む組成物およびその調製
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
MY172578A (en) 2013-05-02 2019-12-03 Novo Nordisk As Oral dosing of glp-1 compounds

Also Published As

Publication number Publication date
CN111494323B (zh) 2023-03-28
HUE064694T2 (hu) 2024-04-28
EP4331667A3 (en) 2024-05-08
CN111494323A (zh) 2020-08-07
US20150031606A1 (en) 2015-01-29
EP2827845B1 (en) 2018-12-26
PL2827845T3 (pl) 2019-06-28
CN111494324A (zh) 2020-08-07
EP2827845A1 (en) 2015-01-28
PL3542790T3 (pl) 2024-02-26
WO2013139695A1 (en) 2013-09-26
JP2015515459A (ja) 2015-05-28
SI2827845T1 (sl) 2019-04-30
JP6356660B2 (ja) 2018-07-11
RS58636B1 (sr) 2019-05-31
EP3542790B1 (en) 2023-09-13
EP4331667A2 (en) 2024-03-06
US10335369B2 (en) 2019-07-02
CN104203221A (zh) 2014-12-10
EP3542790C0 (en) 2023-09-13
EP3542790A1 (en) 2019-09-25
ES2965469T3 (es) 2024-04-15
HRP20231613T1 (hr) 2024-03-15
CN111494324B (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
HUE064694T2 (hu) Továbbítószert tartalmazó készítmények és elõállításuk
IL286348A (en) Pharmaceutical preparations that include allopregnanolone
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
HK1210706A1 (en) Inhalable pharmaceutical compositions
IL252566B (en) Pharmacy preparations and methods
HK1195793A1 (zh) 結合藥物組合物及其用途
HK1201152A1 (en) Dermal delivery compositions and methods
IL236358B (en) Medicinal preparations containing hormone replacements and their use
HRP20190489T1 (hr) Pripravci koji sadrže sredstvo za unošenje i njihova priprava
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
IL236268A0 (en) Preparations for mucosal administration and their uses
EP2753341A4 (en) ANTIMICROBIAL COMPOSITIONS AND USES THEREOF
EP2775831A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
ZA201307837B (en) Compositions comprising antibacterial agent and tazobactam
ZA201504512B (en) Pharmaceutical composition comprising desloratadine and prednisolone and use thereof
PL2908837T3 (pl) Kompozycje do dostarczania leku
EP2926811A4 (en) ARTEMISCULAR PHARMACEUTICAL COMPOSITION, MANUFACTURE AND USE
EP2834635A4 (en) COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
GB201208315D0 (en) Pharmaceutical methods and compositions
EP2838365A4 (en) ANTIMICROBIAL COMPOSITIONS AND USES THEREOF
GB201219884D0 (en) New composition and preparation thereof
GB201110598D0 (en) Pharmaceutical compositions and devices
GB201204970D0 (en) Compositions comprising a combination of morpholinoamino-alcohol and an antimicrobial agent